Detalles de la búsqueda
1.
Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med
; 198(8): 1021-1032, 2018 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29664681
2.
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
Eur Respir J
; 45(4): 969-79, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25573406
3.
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
COPD
; 12(5): 484-93, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25692310
4.
Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
Eur Respir J
; 45(6): 1763, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26028626
5.
Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma.
J Allergy Clin Immunol
; 124(6): 1217-21, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20004781
6.
Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design.
BMJ Open
; 6(4): e010106, 2016 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27075841
7.
Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
Adv Ther
; 32(6): 523-36, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26112656
8.
A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting ß2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
Respir Med
; 109(5): 596-605, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25829298
9.
A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting ß2-agonist, in patients with chronic obstructive pulmonary disease.
Respir Med
; 109(5): 606-15, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25776199
10.
The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.
Springerplus
; 3: 419, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25187881
11.
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Int J Chron Obstruct Pulmon Dis
; 9: 697-714, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25045258
12.
Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Int J Chron Obstruct Pulmon Dis
; 9: 629-45, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24966672
Resultados
1 -
12
de 12
1
Próxima >
>>